Investigational new drugs
-
Investigational new drugs · Jun 2010
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).
Non-Hodgkin's lymphoma (NHL) is the sixth most common cause of cancer deaths in the U. S. Most NHLs initially respond well to chemotherapy, but relapse is common and treatment is often limited due to the toxicity of chemotherapeutic agents. ⋯ IL-PLD exhibits more cytotoxicity than PLD in CD22 positive cell lines but does not increase killing of CD22 negative cells. The IC(50) of IL-PLD is 3.1 to 5.4 times lower than that of PLD in CD22+ cell lines while the IC(50) of IL-PLD is equal to that of PLD in CD22- cells. Furthermore, IL-PLD remained bound to the CD22+ cells after washing and continued to exert cytotoxic effects, while PLD and NL- doxorubicin could easily be washed from these cells.